Skip to main content
OpenTrials
Completed

NCT Number: NCT06033365

Beginning Early and Assertive Treatment for Methamphetamine Use Disorder

The overall goal of the study is to evaluate the effectiveness of a secondary prevention strategy implemented at a systems-level to prevent stimulant related overdoses.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Denver Health

Denver, Colorado, 80204, United States

About this study

To date, a public health systems approach to enhance linkage and engagement in care for stimulant use disorders is lacking. This shortcoming arises in part from the lack of effective treatments for stimulant use disorders (StUD), the specific pathology of methamphetamine use, and gaps in epidemiologic knowledge related to methamphetamine use disorder. Unlike opioid use disorders, for which medications relieve dysphoric symptoms of acute withdrawal and prevent relapse, patients with StUD present to care with methamphetamine-induced psychosis and may be combative, agitated, and poorly insightful to their need for treatment. In response to community demands, our team at Denver Health recently established a pilot program, Beginning Early and Assertive Treatment for Methamphetamine Use Disorder (BEAT Meth), to protocolize the assessment and treatment of patients with methamphetamine-induced psychosis.The current research project aims to develop and conduct process and outcomes evaluations of a linkage intervention aimed at increasing continuation and engagement in treatment for stimulant use disorder.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age and older
  • identified in the Denver Health healthcare system who have had a methamphetamine-related encounter at Denver Health

Exclusion criteria

  • unable to complete the interview in English
  • intoxicated or impaired and unable to consent to participate in the project and/or respond to the interview
  • currently under residential involuntary psychiatric or substance treatment order (i.e., mental health hold, emergency commitment, or short-term certification)
  • received any type of substance use treatment at DHHA in the last 90 days
  • planning to enter substance treatment
  • unable to complete the research visits in the next 90 days

Treatment and study plan

care navigation

Behavioral

Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).

Primary outcomes

  1. Number of participants who entered treatment for methamphetamine use disorder

    Time frame: within 30 of study enrollment

    Treatment entry as defined as attendance at an outpatient addiction treatment appointment within 30 days of BEAT Meth discharge

Secondary outcomes

  1. Number of participants retained in treatment at 30 days

    Time frame: 30 days

    Retention in treatment at 30 days

  2. Number of participants who overdosed

    Time frame: through study completion, an average of 1 year

    non-fatal overdose as self-reported and fatal overdose from medical examiner

  3. Number of participants retained in treatment at 90 days

    Time frame: 90 days

    Retention in treatment at 90 days

Sponsors and collaborators

Lead sponsor

Denver Health and Hospital Authority

Other

Collaborators

  • Centers for Disease Control and Prevention

Registry information

Official study title

Beginning Early and Assertive Treatment for Methamphetamine Use Disorder (BEATMeth): A Comprehensive Systems-level Secondary Prevention Strategy to Prevent Stimulant Related Overdoses

Acronym: BEATMeth

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Sep 13, 2023
Registry last updated
Nov 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.